Associations Between Medication Use and Homocysteine Levels in an Older Population, and Potential Mediation by Vitamin B12 and Folate: Data from the B-PROOF Study
详细信息 查看全文
- 作者：Annelies C. Ham (1)
Anke W. Enneman (1)
Suzanne C. van Dijk (1)
Sadaf Oliai Araghi (1)
Karin M. A. Swart (2)
Evelien Sohl (2)
Janneke P. van Wijngaarden (3)
Nikita L. van der Zwaluw (3)
Elske M. Brouwer-Brolsma (3)
Rosalie A. M. Dhonukshe-Rutten (3)
Natasja M. van Schoor (2)
Tischa J. M. van der Cammen (1)
M. Carola Zillikens (1)
Robert de Jonge (4)
Paul Lips (2) (5)
Lisette C. P. G. M. de Groot (3)
Joyce B. J. van Meurs (1)
André G. Uitterlinden (1) (4) (6)
Renger F. Witkamp (3)
Bruno H. C. Stricker (1) (6)
Nathalie van der Velde (1) (7) - 刊名：Drugs & Aging
- 出版年：2014
- 出版时间：August 2014
- 年：2014
- 卷：31
- 期：8
- 页码：611-621
- 全文大小：351 KB
- 参考文献：1. de Bree A, van der Put NM, Mennen LI, et al. Prevalences of hyperhomocysteinemia, unfavorable cholesterol profile and hypertension in European populations. Eur J Clin Nutr. 2005;59(4):480-. CrossRef
2. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325(7374):1202. mj.325.7374.1202" target="_blank" title="It opens in new window">CrossRef
3. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274(13):1049-7. ma.1995.03530130055028" target="_blank" title="It opens in new window">CrossRef
4. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004;350(20):2042-. CrossRef
5. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004;350(20):2033-1. CrossRef
6. van Wijngaarden JP, Doets EL, Szczecinska A, et al. Vitamin B12, folate, homocysteine, and bone health in adults and elderly people: a systematic review with meta-analyses. J Nutr Metab. 2013;2013:486186.
7. Ford AH, Flicker L, Hankey GJ, et al. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism and cognitive impairment: the Health in Men study. Mol Psychiatry. 2012;17(5):559-6. mp.2011.18" target="_blank" title="It opens in new window">CrossRef
8. Vogel T, Dali-Youcef N, Kaltenbach G, et al. Homocysteine, vitamin B12, folate and cognitive functions: a systematic and critical review of the literature. Int J Clin Pract. 2009;63(7):1061-. CrossRef
9. Stover PJ. Physiology of folate and vitamin B12 in health and disease. Nutr Rev. 2004;62 (6 Pt 2):S3-2; discussion S3.
10. Marti-Carvajal AJ, Sola I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2013;1:CD006612.
11. van Wijngaarden JP, Dhonukshe-Rutten RA, van Schoor NM, et al. Rationale and design of the B-PROOF study, a randomized controlled trial on the effect of supplemental intake of vitamin B12 and folic acid on fracture incidence. BMC Geriatr. 2011;11:80. CrossRef
12. Walker JG, Batterham PJ, Mackinnon AJ, et al. Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms: the Beyond Ageing Project: a randomized controlled trial. Am J Clin Nutr. 2012;95(1):194-03. CrossRef
13. Ford AH, Almeida OP. Effect of homocysteine lowering treatment on cognitive function: a systematic review and meta-analysis of randomized controlled trials. J Alzheimers Dis. 2012;29(1):133-9.
14. Holmes MV, Newcombe P, Hubacek JA, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet. 2011;378(9791):584-4. CrossRef
15. Pham CB, Dickman RL. Minimizing adverse drug events in older patients. Am Fam Physician. 2007;76(12):1837-4.
16. Hayes BD, Klein-Schwartz W, Barrueto Jr F. Polypharmacy and the geriatric patient. Clin Geriatr Med. 2007;23(2):371-0. doi:10.1016/j.cger.2007.01.002 .
17. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017-5. CrossRef
18. Bushardt RL, Massey EB, Simpson TW, et al. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3(2):383-.
19. Desouza C, Keebler M, McNamara DB, et al. Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs. 2002;62(4):605-6. CrossRef
20. Dierkes J, Luley C, Westphal S. Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels. Vasc Health Risk Manag. 2007;3(1):99-08.
21. Mazokopakis EE, Starakis IK. Recommendations for diagnosis and management of metformin-induced vitamin B12 (Cbl) deficiency. Diabetes Res Clin Pract. 2012;97(3):359-7. CrossRef
22. ATC and DDD Index. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway. http://www.whocc.no/atc_ddd_index/.
23. Heil SG, de Jonge R, de Rotte MC, et al. Screening for metabolic vitamin B12 deficiency by holotranscobalamin in patients suspected of vitamin B12 deficiency: a multicentre study. Ann Clin Biochem. 2012;49(Pt 2):184-. CrossRef
24. Whitworth JA. World Health Organization ISoHWG. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983-2. CrossRef
25. Poduri A, Kaur J, Thakur JS, et al. Effect of ACE inhibitors and beta-blockers on homocysteine levels in essential hypertension. J Hum Hypertens. 2008;22(4):289-4. CrossRef
26. Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther. 2013;. doi:10.1177/1074248413497257 .
27. Fan FF, Huo Y, Wang X, et al. Effect of enalapril on plasma homocysteine levels in patients with essential hypertension. J Zhejiang Univ Sci B. 2010;11(8):583-1. CrossRef
28. Westphal S, Rading A, Luley C, et al. Antihypertensive treatment and homocysteine concentrations. Metabolism. 2003;52(3):261-. doi:10.1053/meta.2003.50060 .
29. Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabet Care. 2010;33(1):156-1. CrossRef
30. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340: C2181. doi:10.1136/Bmj.C2181 .
31. Sahin M, Tutuncu NB, Ertugrul D, et al. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. J Diabet Complic. 2007;21(2):118-3. mp.2005.10.005" target="_blank" title="It opens in new window">CrossRef
32. Wulffele MG, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2003;254(5):455-3. CrossRef
33. Fonseca VA, Fink LM, Kern PA. Insulin sensitivity and plasma homocysteine concentrations in non-diabetic obese and normal weight subjects. Atherosclerosis. 2003;167(1):105-. doi:10.1016/S0021-9150(02)00386-6 .
34. Giltay EJ, Hoogeveen EK, Elbers JMH, et al. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. Atherosclerosis. 1998;139(1):197-. CrossRef
35. Dharmarajan TS, Kanagala MR, Murakonda P, et al. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9(3):162-. mda.2007.10.004" target="_blank" title="It opens in new window">CrossRef
36. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004;57(4):422-. CrossRef
37. Mitchell SL, Rockwood K. The association between antiulcer medication and initiation of cobalamin replacement in older persons. J Clin Epidemiol. 2001;54(5):531-. CrossRef
38. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994;120(3):211-. CrossRef
39. van der Loo B, Spring S, Koppensteiner R. High-dose atorvastatin treatment in patients with peripheral arterial disease: effects on platelet aggregation, blood rheology and plasma homocysteine. Clin Hemorheol Microcirc. 2011;47(4):241-1.
40. Jiang S, Chen Q, Venners SA, et al. Effect of simvastatin on plasma homocysteine levels and its modification by MTHFR C677T polymorphism in Chinese patients with primary hyperlipidemia. Cardiovasc Ther. 2013;31(4):e27-3. CrossRef
41. Gorjipour F, Asadi Y, NK Osguei, et al. Serum level of homocysteine, folate and vitamin-B12 in epileptic patients under carbamazepine and sodium valproate treatment: a systematic review and meta-analysis. Iran Red Crescent Med J. 2013;15(3):249-3.
42. Paknahad Z, Chitsaz A, Zadeh AH, et al. Effects of common anti-epileptic drugs on the serum levels of homocysteine and folic acid. Int J Prev Med. 2012;3(Suppl 1):S186-0.
43. Sener U, Zorlu Y, Karaguzel O, et al. Effects of common anti-epileptic drug monotherapy on serum levels of homocysteine, vitamin B12, folic acid and vitamin B6. Seizure. 2006;15(2):79-5. CrossRef
44. Coppola G, Ingrosso D, Operto FF, et al. Role of folic acid depletion on homocysteine serum level in children and adolescents with epilepsy and different MTHFR C677T genotypes. Seizure. 2012;21(5):340-. doi:10.1016/j.seizure.2012.02.011 .
45. Belcastro V, Striano P. Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy. Epilepsy Res. 2012;102(1-):1-. CrossRef
46. Hu XW, Qin SM, Li D, et al. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson’s disease: a meta-analysis. Acta Neurol Scand. 2013;128(2):73-2. doi:10.1111/ane.12106 . CrossRef
47. Klungel OH, de Boer A, Paes AH, et al. Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands. Pharm World Sci. 1999;21(5):217-0. CrossRef
48. Rauma PH, Koivumaa-Honkanen H, Kroger H, et al. The relationship between self-reported and registry-based data on use of psychoactive medications in postmenopausal women. BMC Psychiatry. 2013;13:180. CrossRef
49. Allin S, Bayoumi AM, Law MR, et al. Comparability of self-reported medication use and pharmacy claims data. Health Rep. 2013;24(1):3-.
50. Boudreau DM, Daling JR, Malone KE, et al. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol. 2004;159(3):308-7. doi:10.1093/aje/kwh038 . CrossRef
51. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. JAMA. 1995;274(19):1526-3. ma.1995.03530190040032" target="_blank" title="It opens in new window">CrossRef
52. Ventura P, Panini R, Verlato C, et al. Hyperhomocysteinemia and related factors in 600 hospitalized elderly subjects. Metabolism. 2001;50(12):1466-1. doi:10.1053/meta.2001.28079 .
53. Pongchaidecha M, Srikusalanukul V, Chattananon A, et al. Effect of metformin on plasma homocysteine, vitamin B12 and folic acid: a cross-sectional study in patients with type 2 diabetes mellitus. J Med Assoc Thai. 2004;87(7):780-.
54. Reinstatler L, Qi YP, Williamson RS, et al. Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements: the National Health and Nutrition Examination Survey, 1999-006. Diabet Care. 2012;35(2):327-3. CrossRef
55. Derosa G, Mugellini A, Ciccarelli L, et al. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther. 2003;25(2):472-4. CrossRef
56. Derosa G, Franzetti I, Gadaleta G, et al. Metabolic variations with oral antidiabetic drugs in patients with type 2 diabetes: comparison between glimepiride and metformin. Diabet Nutr Metab. 2004;17(3):143-0.
57. Wang Y, Zhang L, Moslehi R, et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. J Nutr. 2009;139(1):106-2. CrossRef
58. Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;5:951.
59. Zoccolella S, dell-Aquila C, Abruzzese G, et al. Hyperhomocysteinemia in levodopa-treated patients with Parkinson’s disease dementia. Mov Disord. 2009;24(7):1028-3. mds.22511" target="_blank" title="It opens in new window">CrossRef
60. Lamberti P, Zoccolella S, Iliceto G, et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson’s disease patients. Mov Disord. 2005;20(1):69-2. mds.20261" target="_blank" title="It opens in new window">CrossRef
61. Clarke R, Harrison G, Richards S, et al. Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. J Intern Med. 2003;254(1):67-5. CrossRef
62. van Oijen MG, Laheij RJ, Peters WH, et al. Association of aspirin use with vitamin B12 deficiency (results of the BACH study). Am J Cardiol. 2004;94(7):975-. mjcard.2004.06.047" target="_blank" title="It opens in new window">CrossRef - 作者单位：Annelies C. Ham (1)
Anke W. Enneman (1)
Suzanne C. van Dijk (1)
Sadaf Oliai Araghi (1)
Karin M. A. Swart (2)
Evelien Sohl (2)
Janneke P. van Wijngaarden (3)
Nikita L. van der Zwaluw (3)
Elske M. Brouwer-Brolsma (3)
Rosalie A. M. Dhonukshe-Rutten (3)
Natasja M. van Schoor (2)
Tischa J. M. van der Cammen (1)
M. Carola Zillikens (1)
Robert de Jonge (4)
Paul Lips (2) (5)
Lisette C. P. G. M. de Groot (3)
Joyce B. J. van Meurs (1)
André G. Uitterlinden (1) (4) (6)
Renger F. Witkamp (3)
Bruno H. C. Stricker (1) (6)
Nathalie van der Velde (1) (7)
1. Department of Internal Medicine, Erasmus MC, Geriatric Section, University Medical Centre Rotterdam, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands
2. Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research, VU University Medical Centre, Van der Boechorststraat 7, 1081 BT, Amsterdam, The Netherlands
3. Division of Human Nutrition, Wageningen University, P.O. Box 8129, 6700 EV, Wageningen, The Netherlands
4. Department of Clinical Chemistry, Erasmus MC, University Medical Centre Rotterdam, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands
5. Department of Endocrinology, VU University Medical Centre, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands
6. Department of Epidemiology, Erasmus MC, University Medical Centre Rotterdam, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands
7. Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Centre, P.O. Box 22700, 1100 DD, Amsterdam, The Netherlands - ISSN：1179-1969
文摘
Background Elevated homocysteine levels are a risk indicator for cardiovascular disease, fractures and cognitive decline. Previous studies indicated associations between homocysteine levels and medication use, including antihypertensive, lipid-lowering and antidiabetic medication. However, results were often contradictory and inconclusive. Our objective was to study the associations established previously in more detail by sub-classifying medication groups, and investigate the potential mediating role of vitamin B12 and folate status. Materials and Methods Baseline data from the B-PROOF (B-vitamins for the PRevention Of Osteoporotic Fractures) study were used. We included 2,912 participants aged ?5?years, with homocysteine levels of 12-0?μmol/L and creatinine levels ?50?μmol/L, for whom self-reported medication data were available. We used multivariable linear regression models and analysis of covariance to assess the association between medication use and plasma homocysteine levels, and the potential mediation by serum vitamin B12 and folate. Results The mean age was 74?years (standard deviation, 6.5), 50?% were women, and median homocysteine levels were 14?μmol/L [interquartile range, 13-7 μmol/L]. Higher mean homocysteine levels were observed in users vs. non-users for diuretics (15.2 vs. 14.9, p?=?0.043), high-ceiling sulphonamide diuretics (16.0 vs. 14.9, p?p?=?0.029) and metformin (15.6 vs. 15.1, p?=?0.006). Non-selective β-blocker use was associated with lower mean homocysteine levels (14.4 vs. 15.0, p?=?0.019). Only this association was mediated by an underlying association with vitamin B12 and folate levels. Conclusion The associations between homocysteine levels and medication use appear to be fairly modest. Our results suggest that medication use is unlikely to contribute to clinically relevant changes in plasma homocysteine levels.